Tropical eosinophilia (TE) occurs in patients who have filariasis, which is an infection caused by certain types of roundworm, exemplified by Wuchereria bancrofti and Brugia malayi [1]. The presence of these parasites in the body leads to an exaggerated immune response in some individuals characterized by markedly high levels of eosinophils in the blood and even higher concentrations in the lungs [2]. This immune response, in turn, provokes transient episodes of acute respiratory symptoms such as wheezing, coughing, shortness of breath and chest pain, often worse at night [3]. Systemic symptoms such as fever, loss of weight and appetite, lymphadenopathy, hepatomegaly, and splenomegaly may also occur, although, in a small percentage of patients, no pulmonary symptoms are present.

TE is most frequently seen in areas where filarial infections are endemic, however, cases in non-endemic areas have been reported, aided by travel and immigration, albeit some cases are misdiagnosed due to failure to recognize the syndrome [4] [5]. Males are four times more affected by the illness than females. More serious clinical manifestations include permanent widening of the airways, pneumothorax, consolidation of the lungs and granulomas. Cardiac activity can also be affected, and this is demonstrated by electrocardiogram (ECG) abnormalities [6]. Changes in the lung tissue that result in chronic disease have also been reported in a minority of cases, where symptoms do not resolve despite adequate treatment with diethylcarbamazine (DEC) [7].

Patient history is important, especially in non-endemic areas, as a recent travel history to tropical regions may give diagnostic clues. Laboratory investigations such as white cell count as well as measurement of antibody titers are performed. In individuals with TE, leukocytes are increased, with a predominance of eosinophils. Furthermore, there are high titers of specific as well as non-specific immunoglobulins (Ig), namely IgE, IgG, and IgM, in response to filarial antigens [8].

Pulmonary function tests are necessary, and reveal a mixed picture of obstructive and restrictive lung disease, with a decrease in parameters such as the forced expiratory volume (FEV) and the diffusing capacity for carbon monoxide (DLCO) [7] [9]. In some cases, a purely restrictive picture is seen.

In addition, the following studies are also done:

• Arterial blood gas analysis: May reveal lower than normal concentrations of oxygen due to a ventilation-perfusion mismatch [3].
• Chest X-ray: This may be normal in up to one fifth of patients. Usually, widespread nodular opacities are visible, similar to those seen in miliary tuberculosis.
• Computerized tomography scan: Useful in showing structural lung damage such as bronchiectasis [10].
• Bronchoscopy and bronchoalveolar lavage: This allows the visualization of inflammation of the parenchyma as a direct consequence of the presence of a large number of eosinophils in the lungs [2]. Furthermore, anti-filarial antibodies, as well as, nonspecific antibodies can also be seen.
• Lung biopsy: Biopsy is usually done in the context of chronic disease which is first confirmed via spirometry, in the years following treatment.

The primary treatment for Tropical Eosinophilia is antiparasitic medication, such as diethylcarbamazine (DEC), which targets the filarial worms. The treatment course typically lasts for several weeks. In addition to antiparasitic drugs, corticosteroids may be prescribed to manage severe respiratory symptoms. It is crucial to complete the full course of treatment to prevent recurrence.

With appropriate treatment, the prognosis for Tropical Eosinophilia is generally good. Most patients experience significant improvement in symptoms within a few weeks of starting therapy. However, if left untreated, the condition can lead to chronic lung damage and other complications. Early diagnosis and treatment are key to preventing long-term effects.

Tropical Eosinophilia is primarily caused by infection with filarial parasites, such as Wuchereria bancrofti and Brugia malayi. These parasites are transmitted to humans through mosquito bites. Once inside the body, the parasites trigger an immune response, leading to an increase in eosinophils and the associated symptoms.

Tropical Eosinophilia is most commonly found in tropical and subtropical regions, including parts of Asia, Africa, and South America. It is more prevalent in areas where filarial infections are endemic. The condition affects both men and women, typically in their 20s to 40s, and is more common in individuals with prolonged exposure to endemic areas.

The pathophysiology of Tropical Eosinophilia involves an immune response to filarial parasites. The parasites release antigens that stimulate the production of eosinophils. These eosinophils accumulate in the lungs, causing inflammation and respiratory symptoms. The immune response can also lead to systemic symptoms and organ enlargement.

Preventing Tropical Eosinophilia involves reducing exposure to mosquito bites in endemic areas. This can be achieved through the use of insect repellent, wearing protective clothing, and sleeping under mosquito nets. Public health measures to control mosquito populations and mass drug administration in endemic regions can also help reduce the incidence of filarial infections.

Tropical Eosinophilia is a rare but treatable condition caused by filarial parasites. It presents with respiratory and systemic symptoms and is diagnosed through a combination of clinical evaluation and laboratory tests. Treatment with antiparasitic medication is effective, and the prognosis is generally good with timely intervention. Preventive measures focus on reducing mosquito exposure in endemic areas.

If you suspect you have Tropical Eosinophilia, it is important to seek medical evaluation. The condition is associated with symptoms like persistent cough, wheezing, and fatigue, especially if you have traveled to or live in a tropical region. Diagnosis involves blood tests and possibly imaging studies. Treatment is available and effective, so early diagnosis can lead to a full recovery. Preventive measures include avoiding mosquito bites and following public health guidelines in endemic areas.

1. Boggild AK, Keystone JS, Kain KC.Tropical Pulmonary Eosinophilia: A Case Series in a Setting of Nonendemicity. Clin Infect Dis. 2004;39(8):1123-1128.
2. O'Bryan L, Pinkston P, Kumaraswami V, et al. Localized Eosinophil Degranulation Mediates Disease in Tropical Pulmonary Eosinophilia. Infect Immun. 2003;71(3):1337–1342.
3. Ray D, Abel R, Selvaraj KG. Epidemiology of pulmonary eosinophilia in rural South India — a prospective study, 1981–1986. J Epidemiol Community Health. 1993;47(6): 469-474.
4. Jacobson B. Public Health in Inner London. BMJ. 1992;305(6865):1344-1347.
5. Jones DA, Pillai DK, Rathbone BJ, Cookson JB. Persisting ‘asthma’ in tropical pulmonary eosinophilia. Thorax. 1983;38(9):692-693.
6. Vakil RJ. Cardiovascular involvement in tropical eosinophilia. Br Heart J. 1961;23(5):578–586.
7. Poh SC. The course of lung function in treated tropical pulmonary eosinophilia. Thorax. 1974;29(6):710-712.
8. Billa G, Thakkar K. A Case of Chronic Cough with Progressive Breathlessness in a 32 Year-old Male Health Worker -Tuberculosis?, Allergic Bronchitis?, Asthma?. Br J Med Med Res. 2014;4(35):5513-5518.
9. Nesarajah MS. Pulmonary function in tropical eosinophila. Thorax. 1972;27(2):185–187.
10. Sandhu M, Mukhopadhyay S, Sharma SK. Tropical pulmonary eosinophilia: a comparative evaluation of plain chest radiography and computed tomography. Australas Radiol. 1996;40(1):32–37.